Secondary Myelofibrosis Completed Phase 2 Trials for Cyclophosphamide (DB00531)

IndicationStatusPhase
DBCOND0030964 (Secondary Myelofibrosis)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00445900Thalidomide, Prednisone, and Cyclophosphamide in Treating Patients With Myelofibrosis and Myeloid MetaplasiaTreatment
NCT00589563Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological CancerSupportive Care
NCT00611351Busulfan, Cyclophosphamide, and Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic CancerTreatment
NCT01093586Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesTreatment